636. Myelodysplastic Syndromes – Basic and Translational: Poster I

Luspatercept Modulates Inflammation in the Bone Marrow, Restores Effective Erythropoiesis/Hematopoiesis, and Provides Sustained Clinical Benefit Versu

The Association of SEPTIN6 Mutations with Pediatric Myelodysplasia

Lenzilumab in Addition to Azacitidine Improves Complete Response Rates in Chronic Myelomonocytic Leukemia

The Transcriptional Impact of 5q Deletion in MDS at Single Cell Resolution

M41 and Non-M41 UBA1 Variants Differ in Their Alteration of Hematopoiesis

Cytokine and Mutation Profiling Reveal Patterns of Complete Remission Rates with Lenzilumab Combination Therapy in Chronic Myelomonocytic Leukemia

Differential Impact of Domain Stratified Non-R882 DNMT3A Mutations in Myeloid Neoplasms

AG-946, an Activator of Pyruvate Kinase, Improves Ineffective Erythropoiesis in the Bone Marrow of Mouse Models of Myelodysplastic Syndromes